NCT02990611View on ClinicalTrials.gov

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

CompletedOBSERVATIONAL
Enrollment

1,087

Participants

Timeline

Start Date

December 6, 2016

Primary Completion Date

June 20, 2025

Study Completion Date

June 20, 2025

Conditions
Melanoma
Trial Locations (1)

45147

Local Institution - 0001, Essen

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02990611 - Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy | Biotech Hunter | Biotech Hunter